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1. Introduction 
Gliomas account for about 45% of all primary central nervous system (CNS) tumors and 
77% of all malignant primary CNS tumors. Gliomas develop from diverse histological 
lineages, including oligodendrogliomas, astrocytoma and mixed oligoastrocytoma and all 
have the potential to become highly malignant neoplasms. Recent studies in molecular 
biology have better depicted the mechanisms involved in the genesis of cerebral gliomas. It 
is now generally understood that tumor genesis occurs either by over-expression of 
oncogenes or inactivation of tumor suppressor genes. Cerebral gliomas represent an 
interesting target for local gene therapy because of its restricted anatomical location and 
absence of metastases outside the CNS. This allows delivery of vectors directly to the 
desired site only a small risk of systemic toxicity (Immonen et al., 2004). The two main gene 
groups involved in brain tumor development are proto-oncogenes and tumor suppressor 
genes, respectively upregulated and downregulated during the tumor initiation and 
progression. In these processes are activated growth factors signaling pathways, marked 
angiogenesis, downregulation of apoptotic genes and upregulation of antiapoptotic genes. 
The principal proto-oncogenes involved in gliomagenesis encode for growth factors, growth 
factors receptors, or downstream effectors of growth factors function, including c-sis (PDGF-
B chain), erb-B (EGFR), ras (second messenger for GFRs) and myc (transcription factor). 
Other important genes and protein functions involved in brain tumor development are bcl-
2, protein kinase C-ǂ (PKC-ǂ), c-raf-1, protein kinase A-Type I (PKA I), telomerase, MDM2, 
IGF I and insulin-like growth factor I receptor (IGF-IR), HER-2 (encoded from c-erbB-2 
gene), bFGF, fibroblast growth factor receptor (FGFR), TGF-ǂ, TGF-ǃ2, vascular endothelial 
growth factor (VEGF), integrins and genes and proteins involved in the cell cycle control, 
cell proliferation and programmed cell death, angiogenesis and invasiveness pathways. It's 
evident that the modulation of gene expression at more levels, such as DNA, mRNA, 
proteins and transduction signal pathways, may be the most effective modality to 
downregulate or silence specific genic functions. In addition to tumor-suppressor genes and 
proto-oncogenes, there are, also, the suicide genes. These last ones encodes for a non-
mammalian enzyme, that is used to convert a non-toxic prodrug into its active cytotoxic 
metabolite within the cancerous cells.  
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Cancer gene therapy can be subdivided into two main strategies: immunological and 
molecular approaches. The first try to overcome the escape of cancer cells from immune 
system. Despite the initial enphasys of preclinical immune-gene therapy studies, only a few 
of these modalities have entered into human trials for gliomas treatment. Genetic 
immunotherapy can be used mainly to boost T-cell mediated immune response against 
cancer. This approach involves the transfer of the genes of the immune-stimulant molecules, 
such as cytokines. Interleukin-12 gene is one of the most studied cytokine. It has been 
showed complete tumor regression in murine cancer models after interleukin-12 gene 
transfection into hepatocellular carcinoma and adenocarcinoma cells. The production of IL-
12 by tumor cells, after IL-12 gene transfection, mediates activation of cytotoxic T 
lymphocytes and natural killer (NK) cells (Wesseling & Adema, 2009). Direct genetic 
vaccination by the antigen (tumor-specific antigen)-encoding genes, like transfection of in 
vitro engineerized dendritic cells with specific antigens, can also induce the desired 
antitumoral immune reaction (El-Aneed, 2004; Passioura & Symonds, 2004). 
Molecular approaches in cancer gene therapy involve the modulation of oncogenes, tumor-
suppressor genes and suicide genes. One of the most investigated suicide gene/prodrug 
system is the herpes simplex virus thymidine kinase (HSV-tk)/ganciclovir (GCV) system. 
This indirect gene therapy system has been carried out through the delivery of the herpes 
simplex virus thymidine kinase (HSV-tk) gene to the tumor by using an adenovirus vector 
and by transplantating genetically in vitro engineerized cells or inoculation of a recombinant 
defective virus form into a target cell. Adenoviruses transfer their DNA by binding to a 
specific cell surface receptor to form a pore in the endosome to translocate genetic materials 
to the nucleus. The penetration of HSV-tk gene inside only tumoral cells allows the 
synthesis of thymidine kinase protein and the selective death only of  these cells. This 
process lead to intracellular viral replication and exclusive cytolysis of targeted cancer cells; 
the newly released virions from a leased cell could infect the neighboring and distant cells 
but selectively replicate only in cancer cells (Izquierdo et al., 1996). Regarding tumor 
suppressor genes, because their implication in cancer initiation and progression only when 
they are deleted in homozygote pattern, the gene therapeutic strategy with should be 
directed to reach the wild type form of the specific gene function into cancer cell, differently 
than classic antisense therapy that lead to silence specific genic sequences, usually mutated 
and/or amplified oncogenes through inhibitors small RNA or DNA molecules. 
The prognosis for patients affected by brain tumors is influenced by the histological features 
of the neoplasm, the age of the patient and the neurological condition or functional status. 
Despite progresses in microneurosurgical approaches, radiotherapy, radiosurgery and 
chemotherapy as well as in experimental immunotherapy an effective curative treatment of 
gliomas does not yet exist. Mortality, in particular if considered into high-grade gliomas 
cohort, is still close to 100% and the average survival of patients with glioblastoma 
multiforme (GBM) is less than 1 year when classical treatments is used (Gonzalez & Gilbert, 
2005; Stupp et al., 2005). Indeed, progress in treatment of this disease has led only to a slight 
increase in average survival up to 15-18 months. The efficacy of current anti-cancer 
strategies in gliomas is limited by the lack of specific therapies against malignant cells. The 
blood brain barrier limits, moreover, the delivery of many chemotherapeutic agents to the 
central nervous system, contributing to the failure of treatment. An increased site specificity 
and internalization can improve the efficacy of treatment and decrease the possibility of side 
effects.  
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A potential and futurible therapeutic approach in gliomas treatment is represented by 
antisense therapy to block selectively glioma cells, trying to led to revert gliomagenetic 
molecular pathways. This aim could be reached through antisense molecules, delivered 
inside the brain and in particular inside tumoral cells, able to penetrate into glioma cells 
nucleus and to integrate with their genome to silence some specific genic functions. Among 
antisense molecules there are antisense oligonucleotides, ribozymes and RNA interference 
(iRNA). The specificity of hybridization makes antisense method an interesting strategy to 
selectively modulate the expression of genes involved in tumorigenesis. Glial tumors seems 
to be able to create a favorable environment for the invasion of glioma cells in cerebral 
parenchyma when they combine with the extracellular matrix (ECM) via cell surface 
receptors. In clinical oncology there are various interesting examples regarding the efficacy 
of anticancer antisense therapy. Rubenstein et al. published a very interesting findings in an 
in vivo murin model of human PC-3 prostate tumor. The intralesional injection of antisense 
oligonucleotides directed against mRNA encoding TGF-ǂ and its target, EGFR, reached to 
an important hemorrhagic necrosis inside the tumor, directly correlated with cancer cell 
death. Moreover, although direct intratumoral injection of antisense oligonucleotides was 
effective, systemic administration appeared to have a better response rate (Rubenstein et al., 
1996). Similar results have been obtained from Smythe et al. in malignant pleural 
mesothelioma lines REN (epithelial) and 1-45 (sarcomatous), using modified bcl-xl antisense 
oligonucleotides directed near the mRNA initiation sequence. This approach induced 
upregulation of apoptosis in mesothelioma cell lines (Smythe et al., 2002). In this chapter we 
describe the most relevant findings of antisense approach application in glioma treatment 
pointing out the attention on effectiveness, delivery system possibilities, targeting 
modalities and safety of antisense strategy.  
2. Gliomagenesis 
Gliomagenesis is characterized by several biological events, such as activated growth factor 
receptor signaling pathways, downregulation of many apoptotic mechanisms and 
unbalance among proangiogenic and antiangiogenic factors (El-Aneed, 2004; Idbaih et al., 
2008). Several growth factor receptors, such epidermal growth factor receptor (EGFR), 
platelet-derived growth factor receptor (PDRGF), C-Kit, vascular endhotelial growth factor 
receptor (VEGFR) and others growth factors receptors, are overexpressed, amplified and/or 
mutaded in gliomas. Features of the glioma cells are the loss of tumor suppressor genes, 
which are critical for the cell growth, differentiation and function. Table 1 summarizes the 
main genes involved in gliomagenesis.  
2.1 Genetic alterations in gliomas  
Gliomagenesis can develop through two different ways, resulting in evolution of a cluster 
genic alteration directly from normal astrocyte to GBM or by different kinds of mutations of 
various genes passing gradually from normal astrocyte to low-grade glioma, to high-grade 
glioma, to GBM. Primary GBM shows amplification of the epidermal growth factor receptor 
(EGFR), deletion or mutation of homozygous cyclin-dependent kinase (CDK) inhibitor 
p16INK4A/(CDKN2A), alterations in tumor suppressor PTEN on chromosome 10, and 
deletion in the INK4a gene with loss of p14 and p16 (Hanahan & Weinberg, 2000; Holland,  
2001). Progression from low-grade to high-grade astrocytomas involve inactivating 
mutations of tumor-suppressor gene TP53 and elevated expression of platelet-derived 
growth factor (PDGF) ligands and receptors, accumulation of genetic alteration of 
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retinoblastoma-associated cell-cycle regulatory pathways, including deletion or mutations of 
cyclin-dependent kinase inhibitor p16INK4A/(CDKN2A) or the retinoblastoma susceptibility 
locus 1 (pRB1), as well as amplification or over-expression of cyclin-dependent kinase 4 
(CDK4) and human double minute 2 (HDM2). Evolution to secondary GBM is associated 
with deletion of chromosome 10, which includes tumor-suppressor phosphatase and tensin 
homolog (PTEN). Additionally BcI2-like 12 increased expression (BcI2L12) inhibits 
apoptosis (Stegh et al., 2007). The astrocyte elevated gene-1 (AEG-1) is over-expressed in the 
majority of malignant gliomas and stimulates cellular transformation and invasion together 
with the Ha-ras family of retrovirus-associated DNA sequences (RAS) (Ohgaki and Kleihues 
2007). Furthermore, oncogenic Ha-ras induces AEG-1 expression by modulating the 
phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway and contributes to the growth 
of HGGs. Mitogenetic signals activate a molecular cascade known as ras-mitogen activated 
protein kinase (Ras/MAPK). MAPK inhibits the Rb gene, activates the transcriptional factor 
E2F and cells enter the S phase. The INK4a gene influences the Rb pathway by activating 
three cyclin kinase inhibitors: p15, p16, and p19.The final result is the blockage of cyclin-
dependent kinase 2, 4 and 6, triggering cell-cycle progression by inhibiting pRb. 
 
Genes Chromosome Molecular alterations Effects of molecular 
alterations 
3 Cr17p13.1 Mutation Cell cycle control loss, 
proliferation 
PDGF-A 
PDGFR-ǂ  
Cr4q11-q12 Overexpression, 
amplification 
Proliferation, 
invasiveness 
Unknown tumor 
suppressor genes 
1p, 19q, 4q, 
9p, 11p loss 
Loss of heterozygosity Proliferation, 
invasiveness  
Unknown tumor 
suppressor genes 
Cr22q Deletion Proliferation 
Rb 1  Cr13q14.2 Mutations/deletion Cell cycle control 
loss, proliferation 
P16 Cr9p CDKN2/p16 deletion Cell cycle control 
loss, proliferation 
PTEN Cr10q23 LOH Loss regulation  
Akt/PKB pathway 
proliferation,  
tumor growth, 
 invasiveness, 
angiogenesis 
BAX Cr19q24 LOH Pro-apoptotic action 
loss, proliferation 
EGFR (c-erb-2) Cr7p11-p12 Amplification, 
overexpression 
Cell transformation, 
proliferation 
DM2 Cr12q14.3-q15 Overexpression Cell cycle control loss, 
proliferation 
Table 1. Main genes involved in gliomagenesis 
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2.2 Angiogenesis  
Malignant gliomas are characterized by extensive microvascular proliferation and a higher 
degree of vasculature. The formation of new blood vessels from existing microvessels is 
angiogenesis, an histological indicator of the degree of malignancy and prognosis of 
patients. The presence of marked endothelial glomeruloid-like proliferations and of a 
positive immunoreaction at level of basament membrane (BM) in perivascular areas 
demonstrates active tumor invasiveness, disruption of pre-existing anatomical structures 
and neoplastic cellular migration along neoangiogenic vascular channel with evidence of 
proliferation of new fine capillaries (Caffo et al., 2004). Neovascularization in brain tumors 
correlates directly with their biological aggressiveness, degree of malignancy and clinical 
recurrence and inversely with the post-operative survival of patients affected by gliomas. 
Diffuse astrocytomas tend to progress from grade II to grade III tumors with a time interval 
of several years, whereas, progression of grade III to grade IV is more rapid, typically 2 
years. Primary and secondary GBMs are morphologically indistinguishable and show their 
histologic hallmarks, i.e., “glomeruloid” microvascular tufts and necrosis. Glioma 
vasculature is structurally and functionally abnormal and it correlates and leads to 
vasogenic edema, increased interstitial pressure, and eterogeneous delivery of oxygen and 
drugs (Jain et al., 2007). The new vessel growth is stimulated by the secretion of pro-
angiogenic growth factors; these factors bind to receptors on endothelial cells thereby 
activating them. The vascular endothelial growth factor (VEGF) acts as a major vascular 
permeability factor and as a mitogen/survival promoter for endothelial cells. The variant A 
of VEGF (VEGF-A) is secreted by tumor cells as well as by stromal and inflammatory cells. 
VEGF-A can be linked in the extracellular matrix through the interaction with proteoglycans 
or glycosaminoglycans. The expression of the receptors VEGFR1 and VEGFR2 is regulated 
on the endothelial cells in gliomas. The ligands for VEGF3 (VEGF-C&D) are expressed by 
multiple cell types that surround the angiogenic vessels, suggesting the existence of a novel 
pro-angiogenic paracrine signaling pathways in these neoplasms. VEGF expression is 
stimulated by hypoxia and acidosis, and probably correlates with many other growth 
factors and their specific receptors (EGFR, HGFR, PDGFR, C-Kit, IGFR), and their 
downstream signaling pathways (PI3K-Akt, Ras-MAPK) upregulation and activation in 
gliomas. Basic fibroblast growth factor (bFGF) is expressed by vascular cells and, focally, by 
the tumor cells. The receptors for bFGF include FGFR1, expressed by both the tumor cells; 
FGFR2 expressed only by the tumor cells whereas FGFR4 is not detected in gliomas. The 
binding of VEGF on endothelial cells activates the phosphatidylinositol-3-hydroxyl kinase 
(PI3K)/protein kinase B (Akt) pathway, whereas the bFGF receptors are predominantly 
shown through the protein kinase Cǂ (PKCǂ) pathway. The activation of endothelial cells 
results in increased expression of cell adhesion receptors, such us integrins ǂνǃ3 and ǂ5ǃ1, 
and in increased cell survival, proliferation, and migration responses. Many other 
proangiogenic factors are upregulated in gliomas and this aspect might explain the failure of 
many actual antiangiogenic therapeutic strategies in gliomas management. An important 
role has absolved by bFGF, IL-1beta, IL-6, IL-8, TNF-alpha and stromal-cell-derived factor 
(SDF)-1 alpha (Idbaih et al., 2008). The angiopoietins are endothelial growth factors nad 
their signal transduction pathway passes via the Tie2 receptor tyrosine kinase expressed on 
endothelial cells. In particular, Ang-1 and -2, have been implicated in glioma angiogenesis 
(Holash et al., 1999). Ang-1 mediated activation of Tie2 is required for stabilization, 
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remodelling and maturation of blood vessels, promotes angiogenesis and tumor growth and 
is associated with an increased number of highly branched vessels. VEGF and Ang-1 may 
act in concert (proliferation and maturation), while Ang-2 has been implicated in further 
remodeling of the initial microvasculature (Holash et al., 1999). Binding of Ang-2 to the Tie2 
receptor on endothelial cells antagonizes this receptor’s phosphorylation, thereby disrupting 
contacts between endothelial and periendothelial support cells and disengaging pericytes 
from the tumor vessels during initiation of vessel sprouting or regression. Examination of 
the expression patterns of angiopoietins and their receptors suggest a role in GBM 
vasculature and malignant transformation. Ang-2 and Tie2 expression are absent in the 
normal brain vasculature but are induced in tumor endothelium of coopted tumor vessels 
prior to their regression. Treatment of glioma cell derived mouse xenografts with a 
dominant negative form of Tie2 results in a significant decrease in tumor growth (Zadeh et 
al., 2000). The discovery of hypoxia inducible factor-1 (HIF-1) and the observation that 
hypoxia-induced HIF-1ǂ expression in pseudopalisading cells, into intratumoral necrotic 
areas, was concomitant with the expression of one of its target genes, VEGF, established a 
biological link between hypoxia and angiogenesis (Semenza, 2003). During embryonic 
development, blood vessels are newly formed from endothelial precursors and 
hematopoietic stem cells in a process known as vasculogenesis (Yancopoulos et al., 2000). In 
contrast, angiogenesis, the sprouting of new blood vessels from pre-existing ones results 
from an altered balance of proangiogenic factors and antiangiogenic factors. The sequence of 
events leading to the formation of new blood vessels is well characterized and involves an 
initial VEGF-mediated increase of vascular permeability leading to extravasation of plasma 
proteins associated with dilatation of native vessels and reduction in their pericyte coverage. 
Subsequently, endothelial cells migrate and proliferate. For the newly sprouting vessel is 
essential the deposition of proangiogenic matrix. This involves breakdown of the vascular 
basement membrane and extracellular matrix through the action of cathepsin B, matrix 
metalloproteases (MMPs) and other enzymes as well as the expression of matrix proteins 
such as fibronectin, laminin, tenascin-C and vitronectin (Gladson, 1999; Ljubimova et al., 
2006). The angiogenic process culminates in the assembly of endothelial cells to form a 
vascular lumen followed by the elaboration of a new basement membrane and the 
recruitment of pericytes. In contrast to the accepted dogma that tumor development occurs 
in 2 phases (avascular and vascular), we observe that brain tumor growth follows two 
vascular phases. In the first vascular phase, the vessels are native cerebral vessels, which are 
coopted by tumor cells, while in the second phase, there is true neovascularization arising 
from existing vessels. During the transition period between these two phases, hypoxia 
driven HIF-1 expression occurs which results in VEGF secretion and the induction of 
neovascularization. In stage IV, angiogenesis adjacent to the necrotic area is triggered in 
response to increased expression of HIF-1ǂ and VEGF, a process that rescues the remaining 
tumor cells. Thus, it is possible to suggest four sequential steps in glioma progression: i) 
perivascular organization, ii) proliferation, iii) vascular regression followed by necrosis, and 
iv) angiogenesis (Zagzag et al., 2000). 
2.3 Invasion 
Gliomas are almost invariably fatal and recur near the resection margin in almost all cases. It 
is unknown how invasive glioma cells survive in the setting of invasion, how they evade 
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immune detection, how they thwart cytotoxic therapies and defer commitment to 
proliferation. Gliomas show a unique pattern of invasion and with rare exceptions, do not 
metastasize outside of the brain. The discrepancy between the tendency of gliomas to 
infiltrate along anatomically defined pathways with diffuse invasion of brain parenchyma 
and the rarity of metastases to extra-CNS domains remains enigmatic. It is probably possible 
to demonstrate the preference of the tumor cells to migrate along blood vessels and along 
myelinated fibre tracts of white matter, through the analysis of the pathways leading to the 
invasion of gliomas. Invading glioma cells normally migrate to distinct anatomical 
structures. These structures include the basement membrane of blood vessels, the 
subependymal space, the glial limitans externa and parallel and intersecting nerve fiber 
tracts in the white matter. Glioma cell invasion into perilesional tissue consists of an active 
translocation of glioma cells through host cellular and extracellular matrix barriers (Kohn & 
Liotta, 1995). Three steps are fundamental in the phenomenon of glioma invasion: a) 
adhesion of glioma cells to proteins of the surrounding ECM mediated by cell adhesion 
receptors; b) proteases secretion by glioma cells which locally degrade the ECM 
components; c) migration of glioma cells into the newly created space through the ECM. 
ECM is composed of proteoglycans, glycoproteins, glycosaminoglycans and collagens, and 
also contains fibronectin, laminin, type I and IV collagen, tenascin, hyaluronic acid, 
vitronectin. It has turned out that the function of neurons and glia can be understood only in 
relation to their surrounding ECM and that the ECM via specific cell surface receptors play 
an important role in processes such as differentiation, apoptosis, and migration both in the 
normal and the pathologic nervous system. In recent years the glioma invasion has also 
been interpreted by numerous authors in terms of interaction between neoplastic cells and 
ECM. Critical factors include the synthesis and deposition of ECM components by glioma 
and mesenchymal cells, the release of ECM-degrading activities for remodeling interstitial 
spaces, the presence of adhesion molecules (matrix receptors on glioma cell surfaces that 
specifically recognize and adhere to ECM components) and the effects of cell-matrix 
interactions on the behavior of glioma cells. ECM modification aids the loss of contact 
inhibition allowing tumor cells to freely migrate and invade the surrounding tissues. 
Various ECM components, such us hyaluronan, vitronectin, tenascin-C, osteopontin are 
regulated within the tumor stroma and at the advancing edge of the tumor within brain 
parenchyma. Changes in these ECM components are felt to modulate brain tumor growth, 
proliferation and invasion, although specific interactions and exact mechanisms are 
unknown. This process is realized through specific receptors expressed on their surface. The 
integrins, a class of adhesion molecules and the hyaluronan receptor CD44 play a major role 
in glioma cell-matrix adhesion. Integrins regulate many aspects of the cell behavior 
including survival, proliferation, migration and differentiation. Integrins of the ǃ1 and ǂν 
classes are expressed on different cell types, including neurons, glial cells, meningeal and 
endothelial cells. ǃ2 integrins are specifically expressed by leukocytes and they are found on 
microglia and on infiltrating leukocytes within the CNS, ǂνǃ3 integrins is associated with 
elevated levels of its ligands and with vitronectin in human gliomas. The decreasing, in vivo, 
of the ǃ1 subunit by an antisense strategy in the intracranial C6 glioma model leads to a 
integrin, this is highly expressed by tumor cells, at the invasive edge of the tumors  and by 
endothelial cells associated with new blood vessels (Bello et al., 2001). Down-regulated β1 
integrin protein levels in vivo probably affect interactions of glioma cells with ECM 
components, leading to reduced migration along vascular basement membranes. These data 
can be interpreted as a contribute to the locally invasive behavior of astrocytic tumors, 
favoring the regulation of proteases activation. The proteolytic degradation of the basement 
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membrane (BM) is mediated by proteases, such as the matrix metalloproteases (MMPs), 
secreted by tumor and stromal cells. MMPs are secreted as proenzymes and are activated by 
proteolytic cleavage of their amino-terminal domain. MMPs play an important role in 
human brain tumor invasion, probably due to an imbalance between the production of 
MMPs and tissue inhibitor of metalloproteases-1 (TIMP-1) by the tumor cells. Among these 
molecules, MMP-1 is the crucial enzyme able to initiate breakdown of the interstitial 
collagens, collagen type 1, collagen type 2 and collagen type 3; in this way it activates the 
other MMPs which allows the glioma cells to infiltrate normal brain tissue. 
3. The antisense strategy 
Over the last few years, attention has been focused on molecularly approaches. These 
include the development of monoclonal antibodies to specifically target cancer cells and 
small-molecule inhibitors of cell signalling pathways that have been linked to oncogenesis. 
Several approaches are available to specifically manipulate gene expression at the DNA or 
RNA stage of protein synthesis. In eukaryotic organisms, pre-mRNA is transcribed in the 
nucleus, introns are spliced out and then the mature mRNA is exported from the nucleus to 
cytoplasm. The small subunits of the ribosome usually starts by binding to one end of the 
mRNA and is joined there by other eukaryotic initiation factors, forming the initiation 
complex. This multi-enzymatic complex scans along the mRNA strand until it reaches a start 
codon, and then the large subunit of ribosome attaches to the small subunit and translation 
of a protein begins. This process, by which the information of a gene is converted into 
protein, is referred to as “gene expression”. The antisense concept, regarding genic 
expression therapeutic modulation, is based on an understanding of nucleic acid structure 
and function and is dependent on Watson-Crick hybridization mechanisms. The goal of an 
antisense molecules-based approach is to selectively suppress the expression of a protein of 
interest by exploiting the genetic sequence in which it is encoded. The identification and 
validation of antisense inhibitors is the fastest way to identify inhibitors of gene expression. 
Moreover, as they are antisense inhibitors target RNA and not protein, they can be 
extremely specific and versatile in their action when properly used. 
The antisense strategy was first proposed in 1970s. In this study the authors demonstrated 
the feasibility of using short antisense oligodeoxynucleotides to block the expression of 
targeted genes within intact cells. They already documented the use of a tridecamer 
oligonucleotide as a hybridization competitor to inhibit Rous sarcoma virus replication. This 
work provided the first evidence that oligonucleotides could be transported into cells ( 
Stephenson & Zamecnik, 1978). The specificity of Watson–Crick hybridization is the basis 
for rational drug design of antisense oligonucleotides, leading to a new class of selective 
protein synthesis inhibitors The goal of an antisense molecules-based approach is to 
selectively suppress the expression of a protein by exploiting the genetic sequence in which 
it is encoded, acting at translational level (Jansen & Zangemeister-Wittke, 2002; Tamm, 2006; 
Wacheck & Zangemeister-Wittke, 2006). 
Generally, systemic treatment with antisense oligonucleotides is well tolerated and side-
effects are dose-dependent. Dose-limiting toxicities include thrombocytopenia, hypotension, 
fever, and asthenia. Furthermore, an increase in concentration of the liver enzymes aspartate 
aminotransferase and alanine aminotransferase, as well as complement activation and a 
prolonged partial thromboplastin time, have been reported. AONs are relatively small, they 
have short DNA or RNA fragments, 13–25 nucleotides long, with a complementary 
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nucleotidic sequence to sense DNA or mRNA (Baker et al., 2001; Wacheck & Zangemeister-
Wittke, 2006). A DNA single strand or positive sense is normally called “sequence sense”, 
when an RNA version of the same sequence exists and is then translated or translatable into 
protein. Antisense molecules interact with complementary strands of nucleic acids, 
modifying expression of genes. For a cell to use this information, one strand of the DNA 
serves as a template for the synthesis of a complementary strand of RNA. The template 
DNA strand is called the transcribed strand with antisense sequence and the mRNA 
transcript is said to be sense sequence (the complement of antisense). Because the DNA is 
double-stranded, the strand complementary to the antisense sequence is called non-
transcribed strand and has the same sense sequence as the mRNA transcript. These 
antisense molecules may be introduced into a cell to silence one of many genic functions 
through inhibiting translation of a complementary mRNA by base pairing to it and 
physically obstructing the translation machinery. Antisense oligonucleotides inhibit mRNA 
function by several mechanisms, including modulation of splicing and inhibiting protein 
translation by disrupting ribosome assembly. However, the most important mechanism 
appears to be the utilization of endogenous RNase H enzymes (Dean & Bennett,  2003; 
Wacheck & Zangemeister-Wittke, 2006). 
The use of triple-helix forming oligonucleotides or siRNA molecules are promising 
alternatives to antisense oligonucleotides. Although many oligonucleotides reportedly 
demonstrated activity against various viral targets, no oligonucleotide drug has yet been 
approved for routine therapeutic use, except fomivirsen (ISIS 2922), which is an antisense 
oligonucleotide composed of 21 phosphorothioate-linked nucleosides (PS-ON). It is 
administered intraocularly and is used for treatment of cytomegalovirus (CMV) retinitis in 
AIDS patients. However, it needs to be mentioned that this product has only relative 
importance and is only used in special cases, as CMV retinitis can be better treated with 
small molecules like HPMPC (recently approved by FDA and previously already available 
through an investigational newdrug (IND) program). Nevertheless, the approval of 
fomivirsen in 1998 was important to antisense technology as a whole, because it 
demonstrated that antisense drugs can be effective in the treatment of a local disease.  
RNA- and DNA-based oligonucleotides are the most prevalent and most practical antisense 
drugs. There is difference between RNA-based and DNA-based antisense mechanism of 
action. Interactions of RNA-based antisense oligonucleotides with target mRNA inhibit gene 
expression by interfering with protein translation without nevessarily altering mRNA 
stability. Differently, double-stranded DNA/RNA in mammalian cells activates RNase H-
mediated degradation of the target mRNA. RNase H recognizes the mRNA–(DNA) 
oligonucleotide duplex and cleaves the mRNA strand leaving the antisense oligonucleotides 
intact (Jason et al., 2004; Passioura & Symonds, 2004). The arrest of translation by 
oligodeoxynucleotides which hybridize within the coding region or over the initiation 
codon is dependent on cleavage of the targeted mRNA by RNase H. In some cases, but not 
all, binding of antisense sequences to the 5' end of mRNAs was found to inhibit protein 
synthesis directly, presumably by interfering with the initiation of translation. Degradation 
of oligonucleotides in mammalian cells and in blood occurs most rapidly by exonucleases 
that can be blocked by end-group modifications. 
Two alternative antisense-based approaches to modulate gene expression into cancer cells 
are RNA interference and ribozymes. RNA interference (RNAi) has emerged as an efficient 
and selective technique to provide stable inhibition of gene expression. This strategy, 
mediated by small double stranded RNA molecules, is normally an endogenous gene 
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silencing mechanism physiologically used by eukariotes to regulate gene expression by 
reducing protein production and can also be exploited as a reverse genetic tool to study the 
function of genes associated with human diseases and as a therapeutic device to treat 
disease. Moreover RNA interference plays a fundamental role in diverse eukaryotic 
functions including viral defence, chromatin remodelling, genome rearrangement, 
developmental timing, brain morphogenesis, and stem cell maintenance. In mammalian 
cells RNAi can exist under two distinct forms of dsRNA, short interfering RNAs (siRNAs) 
and short hairpin RNAs (shRNAs). These last molecules then are processed into siRNAs by 
the multidomains enzyme DICER in an ATP dependent process. This enzyme is an 
endoribonuclease in the Rnase family that cleaves double-stranded RNA and pre-microRNA 
(miRNA) into short double-stranded RNA fragments called small interfering RNA about 20-
25 nucleotides long. DICER first processes input dsRNA into small fragments called short 
interfering RNAs, or microRNAs, which are the hallmark of RNAi. Dicer then helps load its 
small RNA products into large multiprotein complexes termed RNA induced silencing 
complexes (RISC). RISC and RISC-like complexes use the small RNAs as guides for the 
sequence-specific silencing of cognate genes through mRNA degradation, translational 
inhibition, and heterochromatin formation (Macrae et al., 2006). These siRNAs, through a 
second ATP-dependent molecular step, are then unwound and associate with the 
complementary RNA, through the action of a multiprotein complex known as the RNAi-
induced silencing complex (RISC), and the target mRNA is cleaved within the region of 
complementarity to the siRNA. DsRNA and siRNA activate respectively two different 
molecular pathways. DsRNAs activate endogenous dsRNA-dependent protein kinase 
(PKR), leading to phosphorylation of the translation initiation factor EIF2ǂ and finally to a 
general suppression of protein synthesis and to an upregulation of apoptosis. On the other 
hand, in mammalian cells, siRNAs lead to the knockdown of the target gene expression. The 
limit in clinic and therapeutic use of siRNA to modify strongly gene expression is 
represented from the transient effect of siRNA. These antisense molecules in fact, because of 
mammalian cells lack the RNA-dependent RNA polymerase, should be require the stable 
transfection into target cells by plasmid vectors. A peculiar distinctive characteristic 
between RNA interference and the other antisense approaches (antisense oligonucleotides 
and ribozymes) is the extreme selectivity for substrate from siRNA. In this way these 
antisense molecules may inhibit selectively the expression of oncogene containing a single 
point mutation, without suppress the expression of the wild-type transcript. RNA 
interference-based therapies are available to the targeting oncogenic transcripts in which 
two cellular genes have become fused, leading to the generation of an oncogenic fusion 
protein, such as Bcr-abl in myeloid chronic leukaemia (Jason et al., 2004; Passioura & 
Symonds, 2004). 
Ribozymes have been discovered in the early 1980s. These molecules are catalytic RNA-
RNA enzymes. The first ribozyme discovered was found in the group I intervening 
sequence of the pre-mRNA of Tetrahymena thermophila (Cech et al., 1986) and was shown 
as a ribozyme with the capacity to catalyse its own excision (CIS acting ribozyme). 
4. Molecular targets  
In the last decade there have been various studies that have demonstrated efficacy of 
antisense therapy in vitro and in vivo in oncological diseases and, specifically, in brain 
tumor. Different target molecules at different steps and pathways, such as cell 
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immortalization and apoptosis escape, tumor neoangiogenesis, invasion of normal tissues 
have been studied and chosen as a possible target of new antisense therapeutic model in 
glioma treatment. In table 2 are reported the mainly molecular targets. 
 
Molecular  target Normal function Kind of 
mutation 
Effect of mutation 
Bcl-2 Prevents the release of 
cytochrome C from the 
mitochondria.  
Overexpression  Inhibition of apoptosis 
and increase of resistance 
to chemo- and 
radiotherapies. 
PKC-ǂ Involved in growth-
factor-mediated signal 
transduction pathways. 
Overexpression Upregulation of  cancer 
cell, proliferation and 
tumor growth. 
TGF-ǃ2 
(Glioblastoma-
derived T-cell 
suppressor factor, 
G-TSF, BSC-1 cell 
growth inhibitor) 
It suppresses the effects 
of interleukin dependent 
T-cell tumors. 
Overexpression Downregulation of 
apoptosis and tumor 
growth. Increases ECM 
invasion and induces 
escape of tumor from 
immunosurveillance. 
Telomerase (h-TR)  Reverse transcriptase 
that carries its own RNA 
molecule, which is used 
as a template when it 
elongates telomeres. 
Overexpression Cancer cell 
immortalization, tumor 
growth. 
Focal adhesion 
kinase (FAK) and 
insulin-like growth 
factor I receptor 
(IGF-IR) 
FAK is a protein tyrosine 
kinase which is recruited 
at an early stage to focal 
adhesions, leading the 
cytoskeleton to interact 
with proteins of the 
ECM, and initiate events 
as cell migration and 
anchorage-dependent 
differentiation.  
Transmembrane receptor 
that is activated by IGF-1 
and by the related 
growth factor IGF-2. It 
belongs to the large class 
of tyrosine kinase 
receptors. This receptor 
mediates the effects of 
IGF-1. 
Overexpression 
Gene  
amplification 
Cancer cell proliferation, 
downregulation of 
apoptosis and tumor 
growth. 
PTEN 
(MMAC 1) 
Tumor-suppressor gene 
located on human 
chromosome 10q23.3, 
Nonsense 
mutation, LOH 
Cancer cell proliferation, 
downregulation of 
apoptosis, tumor growth, 
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Molecular  target Normal function Kind of 
mutation 
Effect of mutation 
regulating cell growth, 
apoptosis, interaction 
with ECM and inhibiting 
cell migration, as well as 
spreading and focal 
adhesion.  
invasion. 
PI3K/AKT/PKB 
(pathway of bFGF, 
PDGF, IGF, VEGF, 
EGFR) 
 
Pathway involved in cell 
survival.  AKT has an 
antiapoptotic effect by 
inactivating the 
proapoptotic BAD, 
procaspase-9 and fork-
head transcription factors 
(activation of Fas ligand). 
AKT induces NF-kB-
dependent pro-survival 
genes expression (BCL-
xL, C-Myb), modifies cell 
cycle progression by 
inhibiting p27 and p21, 
up-regulates 
transcription of cyclin D 
and promotes nuclear 
entry of mdm2. 
Overexpression 
Gene 
amplification 
Upregulation of cancer 
cell proliferation, loss of 
cell cycle control, 
increased telomerase 
activity, cell invasiveness 
and angiogenesis by 
stimulating secretion of 
MMPs and by activating 
endothelial nitric oxide 
synthase (eNOS).  
Table 2. Principal molecular pathways involved in gliomagenesis and glioma angiogenesis. 
4.1 BCL-2 
Apoptosis is an important process involved in cell survival. In particular exist two different 
constitutive apoptotic pathways, the extrinsic pathway, that starting from external death 
signals induces the activation of the caspase pathway through initial activation of caspase-8, 
and the intrinsic one. This last pathway involves Bcl-2 family proteins. Inside the extrinsic 
apoptotic pathway, Zhou et al have demonstrated the upregulation of glioma cells apoptosis 
through activation of caspase 9 and 3 (Zhou et al., 2010). 
Bcl-2 gene is one of the most important proto-oncogenes, proptpypical inhibitor of 
apoptosis, located at the breakpoints of t(14;18) chromosomal translocations in low-grade B-
cell non-Hodgkin’s lymphomas. BCL-2 encodes an oncogenic mitochondrial protein with 
transport functions and its expression level is very increased in many types of cancer, such 
as follicular non Hodgkin lymphoma, other lymphomas, leukemias and lung, breast, 
colorectal, gastric, prostate, renal cancer and neuroblastoma. BCL-2 protein prevents the 
release of cytochrome C from the mitochondria (GROSS 99), inhibiting in this way 
apoptosis. Normally, in response to DNA damage, to cellular stress and to other cellular 
damage signals, BCL-2 induces the release of cytochrome c from mitochondrial matrix to 
cytosol, where it activates caspase-9 and caspase-3 through the activation of Apaf-1 (El-
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Aneed, 2004). This overexpression of BCL-2 make it a very promising target for the 
antisense therapy, in consideration also of the BCL-2 protein effect on chemo/radiation 
resistance. In fact, the BCL-2 group of proteins has been implicated not only in the 
pathogenesis of cancer but also in resistance to cancer treatment. Thus, the antisense 
modulation of BCL-2 (mRNA or protein) expression could increase the effectiveness of 
conventional chemotherapeutic agents. A phase II trial is underway with G3139 in 
combination with standard chemotherapy for patients with relapsed, chemotherapy 
resistant non-Hodgkin’s lymphoma. Overexpression of BCL-2 is not uncommon in non-B 
cell malignant tumours. Human melanoma expresses BCL-2 in up to 90% of all cases. Jansen 
and colleagues showed that G3139 improves the chemosensitivity of human melanoma 
transplants in severe combined immunodeficient mice. Additionally, in a phase I/II study, 
Jansen’s group tested the combination of G3139 and dacarbazine in patients with advanced 
malignant melanoma. In a within-patient dose-scalation protocol, G3139 0.6–6.5 mg/kg was 
given intravenously or subcutanously to 14 patients with advanced malignant melanoma 
along with standard dacarbazine treatment. In serial tumour biopsy samples, BCL2 
concentrations were measured by immunoblot, and apoptosis of tumour cells was assayed. 
The combination regimen was well tolerated with no doselimiting toxicity. Haematological 
abnormalities were mild to moderate. Lymphopenia was common. High doses of G3139 
were associated with transient fever. Four patients had liver-function abnormalities that 
resolved within 1 week. Steady-state plasma concentrations of G3139 were obtained within 
24 h and increased with the administered dose as assessed by liquid chromatography. By 
day 5, daily doses of 1.7 mg/kg and higher led to a median decrease of BCL2 expression of 
40% in melanoma samples compared with baseline. Reduced BCL2 expression was 
associated with increased apoptosis of tumour cells. Apoptosis was further enhanced after 
dacarbazine treatment. Six of 14 patients showed antitumour responses. The estimated 
median survival of all patients was more than 12 months, which compares favourably with 
survival of stage IV malignant melanoma patients (usually 6–9 months with and without 
treatment). This study is worth mentioning because it was the first antisense trial in which 
downregulation of the target protein in the target tissue was shown (Jansen & 
Zangemeister-Wittke, 2002). Based on the promising results of this study, the combination of 
dacarbazine and G3139 therapy in patients with malignant melanoma received fast-track 
approval by the FDA, and is in a phase III multicentre trial (Pirollo et al., 2003). Phase I and 
II studies are also being done to test G3139 in combination with docetaxel in patients with 
advanced breast cancer, hormone-refractory prostate cancer, and other solid tumours. 
Another phase I study is analysing the combination of G3139 and mitoxantrone in patients 
with hormone refractory prostate cancer. In 21 individuals treated so far, toxicities were 
transient and included neutropenia (grade 3), lymphopenia (grade 2), fatigue, arthralgias, 
and myalgias (all grade 1). No dose limiting toxicities were reported for the doses tested, 
and one patient had a greater than 50% response to prostate specific antigen with 
symptomatic improvement in bone pain. Another phase I study has been started to test 
G3139 together with salvage chemotherapy of fludarabine and cytarabine in patients with 
refractory or relapsed acute myelogenous leukaemia or acute lymphocytic leukaemia. 
Furthermore, a phase I/II trial of a combination treatment of G3139 and irinotecan has been 
initiated in patients with metastatic or recurrent colorectal cancer. So far, no results are 
available for these two trials. By using antisense oligonucleotides against the first six codons 
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of the human bcl-2 gene transfected into malignant glioma cells (Jon52 and Roc glioblastoma 
cell lines), Julien et al. demonstrated a decrease in cell growth and an increase in apoptotic 
death (Julien et al., 2000). As to BCL2 proteins family role in apoptotic cell death regulation, 
Guensberg et al. showed that resistance to chemotherapy in glioblastoma is linked to the 
expression of antiapoptotic Bcl-2 family members, including Bcl-xL. The authors used anti-
Bcl-xL antisense oligonucleotides (ISIS 16009, ISIS 16967) in M059K glioblastoma cell lines 
and demonstrated a strong correlation between reduction of Bcl-xL protein expression, 
induction of intrinsic apoptotic pathway and enhancement of cytotoxic responses to 
paclitaxel treatment, resulting in a chemosensitizing effect of anti-Bcl-xL therapy 
(Guensberg et al., 2002). 
4.2 Protein Kinase C-α (PKC-α) 
A key regulatorin the glioma cell differentiation and proliferation is protein kinase C-alpha 
(PKC-alpha). This protein, translated from the mRNA of pkc-ǂ gene, located on 
chromosome 16p11.2-q12.1, is a member of  family of cytoplasmic serine-threonine protein 
kinases, strongly involved in growth-factor-mediated signal transduction pathways, in 
order to reach a key role in regulating cell differentiation and proliferation. Its involvement 
in oncogenesis is suggested by the fact that they are the major intracellular receptors for 
tumour-inducing phorbol esters. Among the various PKC isoenzymes, PKC-ǂ may show the 
greatest degree of overexpression in transformed cell lines as compared to normal astrocytes 
in brain tissue peritumoral samples. The overexpression of this transduction signal protein 
has been implicated in various kinds of tumors, such as breast, colon, lung, ovarian cancer, 
melanoma, brain tumors (Campbell & Pollack, 1997; Pirollo  et al., 2003). PKC-ǂ inhibitors 
such as tamoxifen and UCN-01 rich a very high amount of down-regulation of in vitro 
growth and in vivo tumorigenicity. Moreover, numerous in vitro and in vivo animal studies 
have showed the efficacy of antisense oligonucleotides against PKC-ǂ in the cancer growth 
inhibition. ISIS 3521 is the most experimented in order to test the in vitro and in vivo effects 
of the PKC-ǂ downregulation towards cell proliferation and tumors, such as NHL, ovarian 
cancer, NSCLCs, kidney clear cell carcinoma. Results of a phase I study suggested that an 
antisense oligonucleotide directed against PKC-alpha (ISIS 3521) might be effective in the 
treatment of low-grade lymphoma. In this trial ISIS 3521 was delivered over 21 days by 
continuous intravenous infusion followed by a 7-day rest period. In an in vitro study of 
A549 lung epithelia cells, McKay et al. have shown depletion of PKC-ǂ expression by 
antisense oligonucleotides leading to a reduction in c-jun expression but c-fos or junB 
(McKay et al., 1999). This is a crucial pathway in cell growth, cell death and its proliferation. 
The transcription factor c-Jun is one of major targets of JNK phosphorylation. JNK activation 
and c-Jun phosphorylation are involved in the induction of apoptosis (Potapova  et al., 
2000). Inhibition of PKC-ǂ expression, at mRNA level, by a syntetic antisense 
oligonucleotide has been shown to inhibit proliferation of C6 glioma cells and in vitro and in 
vivo growth inhibition of transformed U-87 cells transfected with a PRSV vector loading 
antisense anti-PKC-ǂ oligonucleotide, and, respectively, in vivo subcutaneous 
tumorigenicity lost (Pollack et al., 1996). Grossman et al. studied the therapeutic efficacy and 
toxicity of a phosphorothioate antisense oligonucleotide (Aprinocarsen, Eli Lilly LY9000003) 
directed against PKC-ǂ in patients with recurrent malignant gliomas. In this clinical phase II 
study no clinical benefit was seen, probably because of tumor growth or the effect of 
Aprinocarsen on BBB, whose mechanisms are unknown (Grossman et al., 2004).  
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Other potential therapeutic targets of antisense therapy are human C-raf kinase and c-Ki-
RAS proteins and  signal transduction kinase proteins, involved in the control of 
proliferation, cellular migration, differentiation and cytoskeletal rearrangements. Monia et 
al. demonstrated the evidence of antitumor activity of phosphorothioate antisense inhibitor 
C-raf Kinase (ISIS 5132 or CGP69846A) in tumor-bearing mice, demonstrating an important 
reduction of tumor growth (Monia et al., 1996). Chen et al study has documented a valid 
role of oncogenic Ha-RAS oligo (ISIS 2503) in the proliferation of T24 cells in human bladder 
carcinoma (Chen et al., 1996). 
4.3 TGF-β2 
A key role in gliomagenesis is absolved by TGF-ǃ2 and consequently this growth factor 
represent an important target of antisense therapy. TGF-ǃ2 role in brain tumor and in 
glioma progression in particular was investigated in 1993 by Jachimczak et al. The authors 
demonstrated the efficacy of specific antisense therapy in down-regulation of TGF-ǃ2, 
through stimulation of antitumoral immunosurveillance. In HTZ-153, HTZ-209 and HTZ-
243 glioblastoma and malignant astrocytomas cell lines, TGF-ǃ2 specific phosphorotioate 
antisense oligonucleotides enhanced lymphocyte proliferation up to 2.5 fold and autologous 
tumor cytotoxicity up to 60%. Through an antisense therapy against TGF-ǃ1 and-ǃ2 in 12 
glioma cell lines, another study of the same research group has showed that the effect of 
anti-TGF-ǃ2 phosphorotioate antisense oligonucleotides is much stronger than anti-TGF-ǃ1 
ones (Hau et al., 2009; Jachimczak et al., 1996). This cytokine binds to TGF-ǃ receptors (TBR) 
and initiates a signaling cascade via cytoplasmic signaling mediators (Smads) into the 
nucleus, inducing regulation of target gene expression. Besides this pathways, other 
intracellular TGF- ǃ activated pathways include mitogen- activated protein kinase (MAPK), 
N-RAS, Ral guanine nucleotide exchange factors (Ral-GEF), PI3-K/Akt), c-Jun-NH(2)-
terminal kinase (JNK), p38-P and protein phosphatase 2A (PP2A/p70S6K). During 
tumorigenesis, TGF-ǃ increases extracellular matrix invasion and induces escape of tumor 
from immunosurveillance. In this study antisense compound AP 12009 (antisense 
oligonucleotide anti TGF-ǃ2 mRNA) enhanced the immune cell mediated cytotoxic 
antitumor response against tumor cells (Hau et al., 2007; Schlingensiepen, 2005, 2006). 
Schneider et al. have examined a “double-punched” approach to overcome the escape of 
glioblastoma cells to the immune surveillance, through an active specific immunization 
(ASI) with Newcastle-Disease-Virus infected tumor cells and blocked the TGF-ǃ production 
by delivery of TGF-ǃ antisense oligonucleotides using polybutyl cyanoacrylate NPs. This 
approach induced a significant decrease in plasma TGF-ǃ2 level as well as an increase in 
rate of high affinity IL-2 receptor (CD25) on lymphocytes and consequently of antitumoral 
cytotoxicity (Schneider et al., 2008). 
4.4 Human telomerase 
Kondo et al. demonstrated in vitro and in vivo that anti-hTR antisense treatment suppressed 
tumor cell growth and survival by inducing apoptosis, by treating malignant glioma cells 
(U251-MG cells) in culture with 2-5A antisense oligonucleotide against telomerase RNA and 
by inoculating this antisense molecule directly into tumors induced in nude mice (Kondo et 
al., 1998). This study group showed in vitro that human telomerase antisense inhibition 
induced two different pathways: apoptosis and differentiation in subpopulations of 
malignant glioma cells that escape from apoptotic crisis. Probably, malignant glioma cells 
are cells in G2/M phase in contrast with the major percentage of apoptotic cells that are in S 
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phase of the cell cycle. These results indicate that antisense hTR reduced cell cycling and 
caused an accumulation of cells in G2/M. Treatment of surviving nonapoptotic cells with 
antisense oligonucleotides against p27, but not against p21, (two important cyclin-
dependent kinase inhibitors–CDKIs) induced apoptotic cell death; this suggests that p27 
may have a protective role for the survival of differentiating glioma cells (Kondo et al., 
1998). The efficacy in vitro and in vivo murine model combined with therapy with 2-5A 
anti-hTR and recombinant adenovirus p53 (Ad5CMV-p53) was showed by Komata et al. in 
malignant glioma cell lines with mutant p53 and in vivo GBM murine model (Komata et al., 
2000). By using an antisense oligonucleotide against hTER (the RNA component of 
telomerase), Mukai et al. detected many telomerase-positive tumor cells in the vast majority 
of malignant gliomas (Mukai et al., 2000). In a recent in vitro study (U87-MG and U373-MG 
human malignant glioma cells cultures, cell cultures of human astrocytes expressing 
telomerase with or without oncogenic Ras) and in vivo (murine model) study, it was 
demonstrated that treatment with 2-5A-anti-hTR in the presence of N, N’-bis (2-
chloroethyl)-N.nitrosourea (BCNU), cisplatin (CDDP) and temozolomide (TMZ) better 
enhanced the cell-killing effect if done sequentially rather than concurrently; treatment with 
2-5A-anti-hTR in the presence of paclitaxel (PTX) and Ǆ irradiation (IR) always enhanced 
this effect. The enhanced cell-killing resulted by up-regulation of apoptosis. 2-5A-anti-hTR 
did not impair the autophagy induced by treatment with TMZ or IR and a synergistic 
combined effect. In animal xenograft study model, TMZ enhanced the anti-tumor effect of 2-
5A anti-hTR via induction of apoptosis (Iwado et al., 2007). 
In an in vivo murine model, created by implantation of U-87 MG malignant glioma cells in 
mouse, Im et al. demonstrated the suppression of the ability of glioma cells to form tumors 
in mice. This result was obtained after transfection of antisense VEGF cDNA in an antisense 
orientation through the recombinant adenoviral vector Ad5CMV-ǂVEGF. Infection of U-87 
MG malignant glioma cells resulted in the reduction of the level of the endogenous VEGF 
mRNA and drastically decreased the production of the targeted secretory form of the VEGF 
protein (Im et al., 1999). 
Resnicoff et al. examined the role of IGF-1R in the growth of rat GBM cells and focused the 
attention on IGF-1R pathway, which is critical in the regulation of cell proliferation. In fact, 
neuroglial cell growth and CNS development are normally strongly regulated by IGF-1 and 
IGF-2 via IGF-1R. By introducing  a plasmid expressing an antisense RNA to IGF-1R RNA, 
the study demonstrated the reduction of IGF-1R levels in cell growth in vitro, anchorage-
independent growth and prevention of the development of tumors in rats (Resnicoff et al., 
1994). Andrews et al. observed that IGF-1R AONs-treated autologous glioma cells, collected 
during surgical treatment, were induced toward apoptosis and that, in an in vivo murine 
model, they gave rise to a host response (Andrews et al., 2001). 
Liu et al. showed the crucial involvement of two signal transduction pathways, respectively 
activated by focal adhesion kinase (FAK) and insulin-like growth factor I receptor (IGF-IR) 
kinase into gliomagenesis. In this in vitro and in vivo study (U87 and LN229 glioma cell 
lines and mice bearing intracranial glioma xenografts) the authors demonstrated that 
TAE226, a potent ATP-competitive inhibitor of several tyrosine kinases (such as FAK and 
IGF-IR kinase) down-regulated proliferation and invasion of glioma cells and inhibited cell 
cycle progression particularly at the G2-M checkpoint. TAE226 also gave rise to a 
concomitant reduction of the expression of p-cdc2 (Tyr15) and cyclin B1, increase in 
apoptosis and reduction in glioma invasion in an in vitro Matrigel (Liu et al., 2007). The 
central role of FAK has already been examined in Wu et al. study. By using anti-FAK 
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phosphotothioate antisense oligonucleotides packaging into liposomes in U251 MG cells, the 
authors showed down-regulation of expression levels of FAK and activation of apoptosis, 
through increase in caspase-3 activity, which is a key-mediator of apoptosis in mammalian 
cells. In fact, FAK activates the PI3K survival pathway with the concomitant activation of 
nuclear factor Kappa B (NF-kB) and induction of inhibitor of apoptosis (Wu et al., 2006). 
Another possible interesting target of antisense therapy could be PTEN or MMAC 1, a 
tumor-suppressor gene located on human chromosome 10q23.3, regulating cell growth, 
apoptosis, interaction with extracellular matrix and inhibiting cell migration, as well as 
spreading and focal adhesion. PTEN protein has two different phosphatase activities: a 
lipid-phosphatase activity and a protein-phosphatase activity. Substrates of these specific 
phosphatase activities are phosphatidylinositol 3,4,5-triphosphate and phosphatidylinositol 
3,4-biphosphate; they are both involved in the PI3K FAK pathways. In Park et al. study, it 
was demonstrated that PTEN has an important role in the inhibition of hyaluronic acid-
induced MMP-9 secretion, in the down-regulation of basal levels of MMP-2 and in the 
increase in expression levels of the tissue inhibitor of metalloproteinase-1 and -2 (Park et al., 
2002). 
4.5 PI3K/AKT/PKB pathway 
Among the different growth factors/receptors pathways involved in tumorigenesis of brain 
tumors, such as bFGF, PDGF, IGF, VEGF, EGFR, a crucial role plays PI3K/AKT/protein 
kinase B (PKB) pathway, normally involved in cell survival. AKT is a subfamily of the 
serine/threonine kinases that includes AKT1, AKT2 and AKT3. Growth factors and their 
receptors led to the activation of PI3K, which in turn phosphorilates phosphotidylinositol-
3,4-biphosphate (PIP2) to phosphotidylinositol-3,4,5-triphosphate (PIP3). PIP3 binds to PH 
domain of AKT and gives rise to AKT activation. AKT has an antiapoptotic effect by 
phosphorilating and inactivating the proapoptotic BAD, procaspase-9 and fork-head 
transcription factors. These molecules activate Fas ligand; moreover AKT also induces NF-
kB-dependent transcription of pro-survival genes including BCL-xL, C-Myb, modifies cell 
cycle progression by inhibiting p27 and p21, up-regulates transcription of cyclin D and 
promotes nuclear entry of mdm2. It also leads to degradation of p53 and to uncontrolled cell 
proliferation. AKT enhances telomerase activity and promotes cell invasiveness and 
angiogenesis by stimulating secretion of MMPs and by activating endothelial nitric oxide 
synthase (eNOS). In an in vitro and in vivo murine model, Pu et al. showed the down-
regulation of proliferation rate of C6 glioma cells transfected with antisense AKT2 cDNA 
construct. Parental C6 cells and C6 cells, transfected with antisense construct, were 
stereotactically implanted into the right caudate nucleus of rats through lipofectamine 
complexes. Antisense inhibition of AKT2 resulted in the reduction of growth rate and 
proliferation of C6 cells, as well as in the up-regulation of GFAP expression and in the 
induction of apoptosis (Pu et al., 2006). Inside this crucial molecular pathway, an important 
potential molecular target of gliomas antisense therapy is HER1/EGFR signal transduction 
pathway. This tyrosine kinase receptor can show various kinds of alterations such as gene 
amplification or overproduction of HER1/EGFR ligands. There are various mutant forms of 
HER1/EGFR. The most important mutated hysoform is EGFRvIII, characterized by a 
truncated extracellular domain, is the most studied mutant form; it lacks of a ligand-binding 
domain and is constitutively activated. This mutant form has been detected in several 
human cancers including NSCLC, breast carcinomas, ovarian carcinomas and gliomas. 
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Studies in human GBM cells, in human xenografts models and in GBM patients suggest that 
EGFRvIII promotes tumor growth and progression via constitutive activation of the PI3-
K/Akt pathway; it also induces up-regulation of cell proliferation via the MAPK/ERK1/2 
signal transduction pathway. New therapeutic strategies through small-molecule 
HER1/EGFR TK inhibitors (erlotinib and gefitinib) and monoclonal antibodies (cetuximab) 
may be future therapeutic perspectives in gliomas therapy. The use of antisense RNA into 
murine models of human glioma, through liposomes tagged with monoclonal antibodies, 
facilitates tumor targeting and induces reduction of HER1/EGFR expression increasing 
survival (Halatsch et al., 2006). 
4.6 C-Met/HGF 
C-Met is a tyrosine kinase receptor whose ligand is hepatocyte growth factor (HGF). This 
pathway is very critical in cellular proliferation, motility and invasion and it is over-
expressed in gliomas. Chu et al. demonstrated in vitro and in vivo that AONs against c-Met 
(FAM-labeled c-Met nonsense ODNs-LIPOFECTAMINE PLUSTM GIBCO Laboratories, 
Grand Island, NY) markedly suppressed the expression of c-Met mRNA in human glioma 
cells and cell growth. Inhibition of c-Met gene expression by antisense AONs enhanced 
significantly the cytotoxic effect of radiation on human U251 glioma cells in culture (Chu et 
al., 2006). In a successive research, the same study group showed that c-Met antisense 
oligonucleotides, injected intratumoral in the rat, were well tolerated at therapeutic levels 
and did not produce any toxic effects and recently have increased sensitivity of human 
glioma cells to paclitaxel, leading to a potential targeted-enhanced chemotherapeutic 
approach tightly selective against glioma cells (Chu et al., 2010). 
4.7 ECM proteins 
Khazenzon et al. have demonstrated the effects of antisense inhibition of laminin-8 
expression in glioma therapy through an in vitro model using human glioblastoma 
multiforme cell lines M059K and U-87MG co-cultured with normal human brain 
microvascular endothelial cells (HBMVEC). Endothelial cells contribute laminins containing 
ǂ4 and ǂ5 chains, whereas glial cells synthesize laminins containing ǂ1 and ǂ2 chains. In 
human brain capillaries, laminin-8 is the most expressed laminin. During progression of 
human gliomas, the expression of capillary BM laminins containing ǂ4 chain switches from 
the predominant laminin-9 into lanimin-8. Laminin-8 and its receptor, integrins ǂ3ǃ1 and 
ǂ6ǃ1, are important for the functioning of endothelial cell BMs, which play a role in the 
maintenance of the BBB. Laminin-8 (ǂ4 and ǃ1 chains) plays an important role in glioma cell 
invasiveness, in combination with other proteins associated with glioma progression, such 
as tenascin-C, MMP-2 and MMP-9. In fact, up-regulation of laminin-8 expression in both 
glioma cells and glioma-adjacent capillary endothelial cells may reduce glial cell adhesion 
and enhance migration, which is necessary for local tumor invasiveness. The result of this 
study was a significant reduction of invasion of co-cultures through Matrigel and through 
the use of morpholino oligos against ǂ4 and ǃ1 chains of laminin-8 (Khazenzon et al., 2003). 
4.8 uPAR 
Among the possible key molecules of gliomagenesis, the urokinase-type plasminogen 
activator receptor (uPAR) may be particularly important in regulating plasminogen-
mediated extracellular matrix proteolysis on the cell surface. Through an antisense anti-
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uPAR therapy, Mohanam et al. showed in vitro a markedly lower level of ECM degradation 
with down-regulation of MMP-2 activity and consequently a down-regulation of 
surrounding tissue invasion pathways (Mohanam et al., 1997). 
5. Conclusions 
The treatment of gliomas represents  one of the most challenging areas in neurosurgery and 
oncology. Malignant gliomas involves multiple aberrant signaling pathways and the blood 
brain barrier (BBB) restricts the delivery of many chemotherapeutic agents. The 
efficectiveness of the actual chemotherapeutic approach, multimodal targeted therapies, 
differently than the other malignant extracerebral tumors, remains very modest in gliomas. 
Considering the multitude of molecular entities and signaling pathways regulating the 
proliferation and cellular survival/cell death, the inhibition of a singular target gene or 
transcriptional factor could not be sufficient to suppress neoplastic progression. In this 
intricate and complex field it seems to be very important to improve specific selective drugs 
delivery systems to lead to diffusion of drugs, antisense oligonucleotides, small interference 
RNAs, engineered monoclonal antibodies and other therapeutic molecules into CNS 
overcoming BBB. 
Antisense therapy is an interesting field of base and translational research in cancer therapy. 
This approach has been applied in various kinds of tumors and showed a very high 
specificity and efficacy against cancer cells. Many antisense oligonucleotides have shown 
sharp in vitro reduction in target gene expression and promising activity against a variety of 
human malignancies. Several experimental in vitro and in vivo studies in cell lines cultures 
and animal models showed inhibition of genes involved in cell proliferation, apoptosis and 
angiogenesis. Clinical trials demonstrated a good tolerability and no increment of toxicity of 
antisense oligonucleotides (Caruso et al., 2010a).  
However, considering the multitude of molecular entities and signalling pathways that 
regulate the proliferation and cellular survival/cell death, inhibition of a singular target 
gene or transcriptional factor could not be sufficient to suppress neoplastic progression. 
Glioma cell invasion is a complex and multifactorial mechanism involving a large series of 
molecules and cell-cell and cell-ECM interactions. These processes allow individual tumor 
cells to migrate and invade the surrounding brain parenchyma. ECM, proteases, cell 
adhesion molecules and their related signalling pathways show an important role in glioma 
cell migration and invasion. It is evident that the complexity and cross-talk between signal 
transduction pathways limits the potential efficacy of targeting a single receptor or 
molecule. Future possible interesting molecular target in antisense glioma therapy, tested in 
preclinical study, may be clusterin, eIF-4E (eukaryotic initiation factor-4E), integrins, 
metalloproteinases and other key molecules involved in invasion and angiogenesis.  
We now are investigating about the role of HIF (Hypoxic inducing factor) isoforms and IL-8 
(Interleukine-8) in glioma progression. HIF-1ǂ appears to be a highly involved factor in the 
development of a characteristic tumor phenotype influencing growth rate, invasiveness and 
metastasis. In fact it has to be taken into account that HIF-1ǂ does not only regulate actively 
downstream processes but is also itself influenced by the tumor microenviroment in many 
different ways. As a result, local ipoxia, due to increased proliferation or insufficient oxygen 
supply, inactivation of tumor suppressors, oncogenes and growth factors, along with other 
cell types, such as macrophages, contribute to form a tumor microenviroment capable to 
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modulate the HIF response itself. A highly specific targeting of the organ or tissue is 
mandatory: HIF-1 inhibitors for cancer therapy target the HIF pathway on different levels: 
they decrease HIF mRNA or proteins levels, inhibit DNA binding or decrease HIF-mediated 
transactivation. Antisense inhibition of HIF may be a strong target for anti-angiogenic 
therapy. In fact, HIF is the crucial molecule and transcriptional factor produced in response 
to hypoxic conditions within HIF-1ǂ/VEGF-regulation expression-dependent angiogenic 
pathway. In this molecular cascade HIF-1ǂ up-regulated levels finally induce up-regulation 
of VEGF expression, and, at the same time, may stimulate gene expression of other genes 
involved in gliomagenesis. Our study group has recently showed high expression levels of 
PGES-1 (Prostaglandine E 1 Sinthase) and IL-8 in high grade glioma cells and microglial 
cells, strongly correlated with grading tumor (Caruso et al.,  2010a). 
During malignancy progression gliomagenesis, leukocyte infiltration and necrosis are two 
biological phenomena associated with the development of neovascularization. IL-8 
expression is first observed in low grade astrocytoma in perivascular tumor areas 
expressing inflammatory cytokines. In HGGs, IL-8 further localizes in oxygen-deprived cells 
surrounding necrosis. Macrophages are known to produce high levels of IL-8, which has a 
tumorigenic activity, by inducing tumor growth and angiogenesis; IL-8 is an inflammatory 
chemoattractant responding to the tumor microenvironment. Tumor pseudopalisading cells 
secrete hypoxic inducing factor (HIF) which induces IL-8 secretion. These results support a 
model in which IL-8 expression, by induction of inflammatory stimuli, may be an early step 
in astrocytoma development. IL-8 expression later in tumor progression increases because of 
reduced microenvironmental oxygen pressure. It seems that augmented IL-8 directly 
and/or indirectly promotes angiogenesis by binding to DARC and induces leukocyte 
infiltration and activation by binding to CXCR1 and CXCR2. The contemporary actions of 
IL-8 into glioma angiogenesis and leukocyte infiltration, as well as macrophages, microglial 
cells and ECM components involvement, suggest IL-8 as a future interesting target in 
antitumoral antisense therapy. On the base of our preliminar results, we hypotize an 
important role of IL-8 as crucial angiogenesis mediator within HIF-1ǂ pathway and 
crosstalk between hypoxia-induced high levels of HIF-1ǂ and VEGF expression. To try to 
enhance an anti-angiogenic anti-tumoral effect an attractive therapeutic mechanism may be 
a selective antisense strategy against two molecular targets involved, at different lavels, in 
the same pathological pathway. 
The nanoparticles-based delivery has emerged as a potential method to improve the efficacy 
of the existing detection and treatment options due to the non-toxicity and engineerability of 
nanoparticles. In gliomas treatment, the nanoparticle systems are designed to carry out 
other key functions, including shielding the active drug from producing systemic side 
effects, crossing the BBB, and targeting specific cells after his gained access to CNS (Caruso 
et al., 2010b). 
Nanotechnology deals with structures and devices are emerging as a new field of research at 
the interface of science, engineering and medicine. This approach have the ability to carry 
antisense molecules, such as antisense oligonucleotides, short interfering RNA (siRNA) 
molecules and ribozymes, that, with different modalities, exert RNA interference on target 
gene expression after their internalization into the target tumor cells. Obviously more 
detailed researches about knowledge of cellular biology, and cancer biology will permit 
important progress in the implications of nanotechnology in cancer and naturally in 
malignant gliomas treatment.  
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Glioma gene expression and its development during gliomagenesis will may help to better 
understand the role of important molecules involved in tumor-safe brain parenchyma 
relationships. These molecules, such as ECM proteases, cell adhesion molecules and their 
related signaling pathways show an important role in glioma cell migration and invasion 
and could be selectively attack to inhibits the glioma invasive rim. It is clear that the 
complexity and cross-talk between signal transduction pathways limits the potential efficacy 
of targeting a single receptor or molecule. Antisense targeted therapy is very fashinating 
and probably will be one of the most important strategy to treat high-grade glioma, into a 
multimodal approach for brain tumor treatment. The clinical results of this molecular 
approach are actually very poor, because of the relatively short time of application of this 
kind of strategy in brain tumors, the single molecular target chosen for targeted therapy and 
the anatomic and physiological barriers existing in CNS. Another important aspect to 
valuate is represented by the similarity between the overall survival and progression free 
survival in glioma patients treated according the standard protocol with surgery, 
chemotherapy and radiotherapy versus new experimental molecular multimodal protocol. 
These new future possible targeted antisense-based therapy have showed very interesting 
results in glioma cell lines and in in vivo murine models. On the base of these preliminar 
results and the limits of actual standard therapeutic protocol, we think that antisense 
therapy may be an interesting approach to modify the biological development of gliomas, 
probably trying to modulate crucial pathways of gliomagenesis during precocious steps of 
tumor progression and possibly two or more molecular targets of the same pathway or of 
two different pathways. 
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